Use and Safety of Immunotherapeutic Management of N-Methyl-D-Aspartate Receptor Antibody Encephalitis A Meta-analysis


Creative Commons License

Nosadini M., Eyre M., Molteni E., Thomas T., Irani S. R., Dalmau J., ...Daha Fazla

JAMA NEUROLOGY, cilt.78, sa.11, ss.1333-1344, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 78 Sayı: 11
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1001/jamaneurol.2021.3188
  • Dergi Adı: JAMA NEUROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Psycinfo
  • Sayfa Sayıları: ss.1333-1344
  • Hacettepe Üniversitesi Adresli: Hayır

Özet

IMPORTANCE Overall, immunotherapy has been shown to improve outcomes and reduce relapses in individuals with N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis (NMDARE); however, the superiority of specific treatments and combinations remains unclear.